Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652723 | 0.88 | CYP19A1 (0.44) | CYP19A1CYP11B1CYP11B2NPC1GAA | |
| SCHEMBL2651961 | 0.85 | ALDH1A1 (0.51) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL10672549 | 0.75 | TBXAS1 (0.73) | CYP19A1NPC1POLBTBXAS1 | |
| SCHEMBL9683164 | 0.74 | GAA (0.70) | NPC1GAAGFERPOLBKDM4E | |
| SCHEMBL6033876 | 0.74 | CYP19A1 (0.69) | CYP19A1CYP11B1CYP11B2NPC1POLB | |
| SCHEMBL2652140 | 0.74 | CYP19A1 (0.44) | CYP19A1 | |
| SCHEMBL15020894 | 0.74 | GAA (0.60) | NPC1GAAGFERKDM4E | |
| SCHEMBL27481116 | 0.73 | TBXAS1 (0.54) | CYP19A1CYP11B1CYP11B2AGTR2TBXAS1 | |
| SCHEMBL4002584 | 0.73 | GAA (0.72) | NPC1GAAGFERKDM4E | |
| SCHEMBL23675160 | 0.73 | GAA (0.58) | NPC1GAAGFERKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194410-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH AS (DK) | 2006-01-18 | — | — | EP | disclosed |
| US-6936613-B2 | Benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
| EP-1194410-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | CYP19A1 1441/4885CYP11B1 81/4885CYP11B2 50/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | CYP19A1 1744/4885CYP11B1 82/4885CYP11B2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.